Leadership Team

Composed of highly qualified professionals, the management team works daily to carry out the current and strategic activities of the Company.

JOIN US

Come work at Theratechologies

Theratechnologies is constantly looking for talented, energetic people that share our values.

Paul Lévesque

President and Chief Executive Officer

Paul Lévesque has built an enviable reputation in the pharmaceutical industry both here and abroad. He is recognized for his track record at delivering growth.

Paul has worked in the research-based pharmaceutical industry since 1985. He started with Upjohn Canada and then joined Pfizer Canada in 1992. He went on to occupy increasingly senior positions within the organization including as Vice President of Marketing in Canada and in France, Country Manager for Canada, Chief Marketing Officer for the U.S. in Primary Care and as Regional President in Asia-Pacific for the innovative division of Pfizer.

He also assumed the role of Global President for the Rare Disease Unit until he joined Theratechnologies on April 6, 2020.

Paul carries a passion for bringing to patients’ therapies in areas of unmet medical needs and will put to contribution his learnings from his 35 years in the pharmaceutical industry.

Paul holds a BSc in biochemistry from Laval University and a Diploma in Management from McGill University. Paul is married and has three children.

Jovan Antunovic, MBA, M.Sc.

Senior Vice President and Chief Commercial Officer

Mr. Antunovic has over 20 years of experience in the commercialization of innovative pharmaceutical products, medical equipment and diagnostics. Most of his career has been in specialty pharmaceuticals where he has held various senior management roles with increasing responsibility at Abbott in Canada, Europe and Japan and at Abbvie and Bristol-Myers Squibb in Canada. Mr. Antunovic has also been involved in several product launches in the U.S. and Europe and has worked in over 10 different therapeutic areas, including HIV.

 

Mr. Antunovic graduated from McGill University in 1991 with a Bachelor’s degree (Honours) in Biochemistry. He also completed a Master’s degree at McGill University in 1994, during which he published three articles. He obtained a Master of Business Administration from McGill University in 1997 where he specialized in marketing.

 

Mr. Antunovic joined Theratechnologies in December 2018.

Denis Boucher, B.A., LL.B

Vice President, Communications and Corporate Affairs

Mr. Boucher joined the Corporation in January, 2018 and brings more than 30 years of experience in communications, government affairs and crisis management.

 

Prior to joining Theratechnologies, Mr. Boucher practiced litigation and labour and employment law at a firm in the region of Montreal. He was previously a partner for 15 years Canada’s largest public relations firm where he was in charge of the healthcare practice and business development. He was hired after spending close to five years as Manager, Public Affairs at Merck Frosst. Mr. Boucher started his career as a television news reporter at Société Radio-Canada in Toronto and was then appointed press secretary to the President of Treasury Board in Ottawa.

 

Mr. Boucher holds a Bachelor of Arts Degree from Université Laval in Québec City as well as a Law Degree from Université de Montréal. He was called to the Quebec Bar in 2016. Upon completing a training at the Harvard Negotiation Institute in Cambridge, Massachusetts, in 2016, he was accredited by the Quebec Bar as a mediator in civil, commercial and labour law.

Marie-Noël Colussi, CPA, CA

Vice President, Finance

Ms.Marie-Noël Colussi is a graduate of Université du Québec à Montréal in business administration.

 

Prior to joining Theratechnologies, Ms. Colussi worked for eight years with KPMG, a major accounting firm. Ms. Colussi has acquired sound experience in accounting, auditing, control and taxation, particularly in R&D. She joined Theratechnologies in March 1997, and prior to her appointment as Vice President, Finance in February 2002, she successively held the positions of Director, Accounting and Internal Control as well as Controller.

Philippe Dubuc, MBA

Senior Vice President and Chief Financial Officer

Mr.Dubuc brings more than 25 years of experience in investment banking in the healthcare sector and in management.

 

He started his career as a management consultant at Groupe Secor, a well-known Quebec-based consulting firm which is now part of KPMG. He then served as Managing Director, Investment Banking at National Bank Financial. In this role, he headed the healthcare group and was involved in numerous financing and M&A transactions. He later founded a manufacturing company which he sold after seven years of successful operations.

 

Mr. Dubuc holds a M.B.A. from McGill University and a B.Comm. from Concordia University. Mr. Dubuc joined Theratechnologies in February 2016.

Jocelyn Lafond, LL.B., LL.M.

Vice President, Legal Affairs, and Corporate Secretary

Mr.Lafond has over 20 years of experience in the fields of corporate and securities laws.

 

Mr. Lafond holds a law degree from Université Laval and a Masters Degree in Law from the University of Toronto. He has been a member of the Barreau du Québec since 1992. Prior to joining Theratechnologies, Mr. Lafond was a partner with the international law firm of Fasken Martineau DuMoulin, LLP.

Christian Marsolais, Ph. D.

Senior Vice President and Chief Medical Officer

Dr.Christian Marsolais has over 25 years of experience in the research, development and commercialization of new drugs. He started his career in international pharmaceutical companies, including Sandoz, Biochem and Pfizer, where he held different positions from medical advisor to director clinical research and medical affairs. He was also appointed to the global oncology team at Pfizer, which managed the global oncology portfolio.

 

Dr. Marsolais joined Theratechnologies in 2007, and lead the medical team which was central to the approval of Egrifta by the US FDA. He was also instrumental in the efforts that lead to the US and European acquisition of the commercial rights for Trogarzo and the approval of Trogarzo by the US FDA. More recently, he also lead the team to pursue the approval of Trogarzo in Europe.

 

Dr. Marsolais holds a Ph.D. in biochemistry from the Université de Montréal.

Conor Walshe, B.Comm, MBS , FCA

General Manager, Europe

Mr. Walshe is based at the Theratechnologies European head office in Dublin, Ireland. Prior to joining our European subsidiary, Mr. Walshe was General Manager and Vice President, Operations and Commercial, at Aralez Plc. Prior to Aralez Plc, Mr. Walshe spent more than 15 years in the pharmaceutical industry including at Perrigo Plc, Elan Plc and Venn Life Sciences where he was called upon to serve, among others, as CFO, Senior Vice President Commercial and Financial Operations and in product management.

 

Mr. Walshe is a Chartered Accountant. He holds a Bachelor of Commerce and a Master in Business Studies from the University College in Dublin. He also obtained a diploma in IFRS from the Institute of Chartered Accountants and in Advanced International Corporate Finance from INSEAD.